PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 4 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $382,000 | -27.2% | 100,482 | -2.7% | 0.00% | – |
Q4 2019 | $525,000 | 0.0% | 103,234 | -0.5% | 0.00% | -100.0% |
Q3 2019 | $525,000 | -66.6% | 103,785 | -59.3% | 0.00% | 0.0% |
Q2 2019 | $1,573,000 | +38.8% | 254,909 | +4.4% | 0.00% | 0.0% |
Q1 2019 | $1,133,000 | +9.8% | 244,265 | -0.6% | 0.00% | 0.0% |
Q4 2018 | $1,032,000 | -35.3% | 245,655 | -3.5% | 0.00% | 0.0% |
Q3 2018 | $1,596,000 | -14.8% | 254,619 | +9.3% | 0.00% | -50.0% |
Q2 2018 | $1,873,000 | +7.2% | 232,984 | -0.6% | 0.00% | 0.0% |
Q1 2018 | $1,748,000 | +47.8% | 234,314 | +17.8% | 0.00% | +100.0% |
Q4 2017 | $1,183,000 | -20.2% | 198,852 | -1.3% | 0.00% | 0.0% |
Q3 2017 | $1,483,000 | +6.9% | 201,523 | -1.3% | 0.00% | 0.0% |
Q2 2017 | $1,387,000 | -29.3% | 204,202 | -1.7% | 0.00% | -50.0% |
Q1 2017 | $1,962,000 | +7.6% | 207,837 | -1.5% | 0.00% | 0.0% |
Q4 2016 | $1,823,000 | +29.9% | 211,010 | -4.8% | 0.00% | +100.0% |
Q3 2016 | $1,403,000 | – | 221,644 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Phocas Financial Corp. | 1,033,328 | $6,376,000 | 0.68% |
ARDSLEY ADVISORY PARTNERS LP | 650,000 | $4,011,000 | 0.63% |
Worth Venture Partners, LLC | 138,357 | $853,000 | 0.47% |
RICE HALL JAMES & ASSOCIATES, LLC | 2,242,503 | $13,836,000 | 0.46% |
HIGHLAND CAPITAL MANAGEMENT LP | 716,880 | $4,423,000 | 0.26% |
FARALLON CAPITAL MANAGEMENT LLC | 5,543,386 | $34,203,000 | 0.22% |
Point72 Asset Management, L.P. | 5,858,749 | $36,148,000 | 0.19% |
PINNACLE ASSOCIATES LTD | 1,298,723 | $8,013,000 | 0.19% |
Fosun International Ltd | 472,580 | $2,750,000 | 0.18% |
J. Goldman & Co LP | 400,000 | $2,468,000 | 0.17% |